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Abstract
Background: The validation of international cognitive batteries in different multiple sclerosis (MS) populations
is essential. Our objective was to obtain normative data for the Portuguese population of the Brief International Cognitive
Assessment for Multiple Sclerosis (BICAMS) and assess its reliability.
Methods: The BICAMS was applied to 105 MS patients and 60 age, gender and education matched healthy controls
(HC). In order to test its reliability, BICAMS was re-administered in a subset of 25 patients after a 7-month interval.
Results: Most participants were women, with a mean age of 37, 21 years and a mean of 14,08 years of education. The
vast majority of the MS patients (92.4%) had the relapsing remitting type, 58.1% were professionally active, mean disease
duration was 6.52 years, median EDSS score was 1.5 (range: 0–6.0) and the median MSSS score was 2.01 (IQR range: 3.83).
The MS group presented significantly higher scores of anxiety and depression than HC and 47,4% had fatigue. The MS
group performed significantly worse than the control group across the three neuropsychological tests, yielding the
following values: SDMT: t(165) = 3.77, p = .000; CVLT-II: t(165) = 2.98, p = .003; and BVMT-R: t(165) = 2.94, p = .004.
The mean raw scores for Portuguese normative data were as follows: SDMT: 58.68 ± 10.02; CVLT-II: 60.47 ± 10.12;
and BVMT-R: 24.68 ± 5.52. Finally, test–retest reliability coefficients for each test were as follows: SDMT: r = .90;
CVLT-II: r = .71; and BVMT-R: r = .84.
Conclusions: The Portuguese version of BICAMS here in described is a reliable monitoring instrument for identifying
MS patients with cognitive impairment.
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Background
Multiple sclerosis (MS) is a chronic inflammatory de-
myelinating disease of the central nervous system that
can impair any body function, including cognition [1].
Cognitive dysfunction affects 40 to 70% patients [2, 3].
Irrespective of age and gender [3, 4], may occur at all
stages of the disease, even at the very early beginning [5,
6] and definitely impacts the lives of MS patients and
their families [3, 7, 8].
The characteristic pattern of cognitive impairment in
MS has been described early on to include memory, in-
formation processing efficiency, executive functioning,
attention and processing speed [1]. However, the cogni-
tive domains most likely to be affected in MS are infor-
mation processing speed and memory, whilst visual
processing and executive function are less likely to be
impaired and language is largely intact [1, 9–12].
The most frequently used neuropsychological batteries
for patients with MS such us, the Brief Repeatable Bat-
tery of Neuropsychological tests and the Minimal
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Assessment of Cognitive Function in MS, require spe-
cialized technical and human resources and take a con-
siderable time for evaluation in the daily clinical setting
[1, 13]. Recently, the Brief International Cognitive As-
sessment for MS (BICAMS) was developed and recom-
mended as a validated and standardized international
screening test, because it is an easier assessment tool
that can be administered by a technician who is not a
specialist in neuropsychology and lasts only about
15 min to apply [14, 15]. Besides, the three instruments
that compose BICAMS – Symbol Digit Modalities Test
(SDMT) [16], California Verbal Learning Test (CVLT-II)
[17] and Brief Visuo-spatial Memory Test Revised
(BVMT-R) [18] – have previously been shown to have
good psychometric properties.
The aims of this study are to describe the normative
values of the Portuguese version of the BICAMS with
gender, age and education corrections and to test the




A group of 105 patients with MS diagnosed according to
the McDonald criteria [19] and a control group of 60
age, gender and education matched healthy subjects
(HC), entered this study, and conducted in the period
2015–2016.
The MS patients were consecutively recruited at the
MS Clinics from two hospitals located in separate re-
gions of the country, Hospital de São João (Oporto;
North) and Hospital Beatriz Ângelo (Loures; South),
whereas the HC group was recruited from the commu-
nity and among relatives and friends of MS patients. All
participants were aged between 17 and 69 years and they
were fluent in Portuguese as first language.
Exclusion criteria were current or past neurological
disorder other than MS, presence of major psychiatric
illness, history of learning disability, history of serious
head trauma, presence of alcohol or drug abuse, relapse
and/or corticosteroid use within 4 weeks preceding the
neuropsychological assessment. HC were also required
to present scores > 21 on Montreal Cognitive Assess-
ment Portuguese version (MoCA) [20, 21].
The study was approved by the ethical committees of
both hospitals. All the participants, from MS group and
HC, volunteered to participate in this study, giving writ-
ten informed consent.
Procedures
An initial demographic interview was conducted. This
was based on a common script that included a demo-
graphic questionnaire, medical history, drinking and
drug habits and present health status. The MS data, such
as type, duration, and degree of disability and severity, as
assessed by the Expanded Disability Status Scale (EDSS)
[22] score and the Multiple Severity Status Score (MSSS)
[23], respectively, were obtained in the clinical protocols.
Then, participants underwent the BICAMS battery
[14], which included the oral version of Symbol Digit
Modalities Test (SDMT) [16], the learning trials from
the California Verbal Learning Test-II (CVLT-II) [17]
and the Brief Visuo-spatial Memory Test-Revised learn-
ing trials (BVMT-R) [18].
The SDMT [16] examines sustained attention, concen-
tration and processing speed. In the oral version, the
participant examines a series of nine meaningless geo-
metric symbols, which are labeled from 1 to 9. Then,
during 90 s the participant is instructed to say the corre-
sponding number to each symbol, as rapidly as possible.
The test score corresponds to the number of correct
responses.
The CVLT-II [17] is a measure of verbal learning and
memory. The test begins with the examiner reading a list
of 16 words to the patient and then he/she is asked to
report as many of the items as possible, in any order.
After recall is recorded, the entire list is read again
followed by a second attempt at recall. Altogether, there
are five learning trials. The outcome measure is the total
number of recalled items over the five learning trials.
The BVMT-R [18] is a measure of visuo-spatial learning
and memory. The participant is exposed to a matrix of six
simple abstract designs for 10 s followed by an unaided re-
call; we used the form 1 of the original test. After that, the
participant is asked to render the designs using paper and
pencil, taking as much time as needed for reproduction.
The scoring criterion is based on location and accuracy of
each design (from 0 to 2, maximum total score for each
array 12). The outcome measure of this test corresponds
to the total recall score across the three trials.
The validation was conducted per the international
standards given by the expert consensus committee [15].
As the first step, the CVLT-II list of words were trans-
lated and re-translated from English to Portuguese and
vice versa respectively; the other two tests did not re-
quire translation due to their nature. In the second step,
the test instructions were translated into Portuguese.
In both groups, anxiety and depression symptoms
were also measured using the Portuguese version of
Hospital Anxiety and Depression Scale (HADS) [24]. In
the MS group the level of fatigue was measured with the
Modified Fatigue Impact Scale (MFIS) [25–27].
“The participants of both groups were asked to return
for a follow-up session to allow for test–retest reliability
analyses. A subgroup of 26 patients and 13 HC returned
after a mean time of 7 months and all the tests adminis-
tered in the first session were repeated in the same man-
ner and in the same order.”
Sousa et al. BMC Neurology  (2018) 18:172 Page 2 of 7
Well-trained clinical psychologists conducted all ses-
sions and the tests were applied in a standardized way
and in a fixed order. The mean time for BICAMS appli-
cation was 15 min, as described [14, 15].
Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences (IBM SPSS), version
23.0. Descriptive statistics (e.g., mean, standard devi-
ation, median, interquartile range and percentages) were
used for demographic characterization of both groups.
Student’s t-test for independent samples was used to
analyze the differences between groups, at the level of p
< .05. The values shown in the tables are bilateral
p-values. The effect sizes of those differences were calcu-
lated using Cohen’s d. Spearman’s correlations (Ρ) were
used to analyze reliability measures and the relationship
between BICAMS, HADS and MFIS results. Raw scores
were analyzed for the full sample and Z-scores were cal-
culated. Multiple regression analysis was used to pro-
duce normative data.
Results
Demographics and MS characteristics
The groups were similar with regard to age (MS group:
M = 38.26 years±11.03; HC: M = 36.17 years ±12.01,
p = .63), gender (MS group: %Female = 66.7; HC: %Fe-
male = 58.3, p = .28) or number of educational years (MS
group: M = 13.55 ± 3.71; HC: M = 14.62 ± 3.47, p = .42).
With respect to professional status, the majority of sub-
jects were employed, with a much higher proportion of
HC than MS, as is usually reported (n = 56, 94.9%; n =
61, 58.1%, respectively). In the MS group, 92,4% (n = 97)
of patients had the relapsing remitting type and 3,8%
(n = 4) secondary progressive type and 3,8% (n = 4) clin-
ically isolated syndrome. The average disease duration
was 6.52 years (SD = 5.95) and the median EDSS score
was 1.5 (range: 0–6.0). The MSSS score, calculated in
patients from 1 to 30 years of disease duration (n = 95),
had a median value of 2.01 (IQR range: 3.83).
Criterion-related validity: Group differences
Means, standard deviations and t test’s for independent
samples from the three tests are presented in Table 1.
The results showed that MS group performed signifi-
cantly worse than the HC group on all measures.
Cohen’s d was analyzed for each neuropsychological test
and were satisfactory: SDMT - 0.65 (large); CVLT-II -
0.49 (medium); BVMT-R - 0.45 (medium) [28].
Reliability: Test-retest
The test–retest reliability data obtained in a subgroup of
MS patients are presented in Table 2. The test-retest re-
liability coefficients showed a strong to a very strong and
significant effect for all BICAMS tests.
The test-retest results in the HC were not considered
in view of the low number of cases.
Regression based-norms
To obtain a regression-based normative model for
BICAMS, the distribution of the SDMT, CVLT-II and
BVMT-R raw scores was analyzed for the complete sam-
ple and the Z scores were calculated. The raw scores
were then converted into scaled scores (M = 10 and SD
= 3), as presented in Table 3. For each test a multiple re-
gression analysis with a stepwise method using the
scaled scores as dependent variable and age, gender and
education as predictors was performed. Education was
introduced as the number of regular academic school
years that the participant successfully completed. As
some studies suggest that there is a curvilinear relation-
ship between demographic variables and cognitive func-
tion [29], the quadratic term of age and education were
also introduced as predictors. These results allow us to
detect which variables contributed significantly to ex-
plain each of the scaled neuropsychological test scores.
The T-scores corrected for education, age and gender
were generated through a procedure suggested by Diehr
and colleagues [30]. Therefore, another multiple regres-
sion (enter method) with each of the BICAMS test
scaled scores as the dependent variable and the signifi-
cant predictors of each test was performed. The
non-standardized predicted values of this equation were
saved and a new variable was calculated corresponding
to the difference between an individual’s actual and pre-
dicted scale score (i.e., the residual) divided by the stand-
ard deviation of those residuals. These values were then
rescaled for a T-score (M = 50 and SD = 10).
Finally, another multiple regression analysis with cor-
rected T-score as the dependent variable was performed
to generate each test normative formula for the






SDMT 51.77 (11.20) 58.68 (10.02) 3.77 0.000
CVLT-II 55.05 (11.84) 60.47 (10.12) 2.98 0.003
BVMT-R 21.72 (7.27) 24.68 (5.52) 2.94 0.004
Table 2 Test–retest means and correlations for MS group (n = 26)
Time 1 Time 2 Spearman’s
correlation
P
Mean SD Mean SD
SDMT 50.96 11.56 53.92 13.99 0.90 < 0.001
CVLT-II 57.08 12.75 57.31 17.44 0.71 < 0.001
BVMT-R 22.00 7.43 25.12 6.94 0.84 < 0.001
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Portuguese population. The final formula to calculate
the T-scores for each of BICAMS’s test are presented
below:
SDMT T score ¼ 10:511þ 0:007 age2 
þ −0:966 years of educationð Þ
þ 4:138 scaled scoreð Þ
CVLT−II T score ¼ 3:195þ 0:006 age2 
þ 3:761 scaled scoreð Þ
BVMT−R T score ¼ −8:004þ 0:514 ageð Þ
þ 3; 833 scaled scoreð Þ
In determining impairment, the 5th percentile value
based on the performance of healthy control sample was
calculated for each test. Participants were considered im-
paired if their score was equal of below the percentile
5thof the control group (results are presented on the
Table 4) [31]. Then, using the previously reported cri-
teria of impairment defined by “one or more abnormal
tests” [32, 33], it was found that 24.8% of the MS sample
was impaired at baseline.
Analysing the degree of disability assessed by EDSS
and cognitive performance, we found significant correla-
tions with all cognitive tests (SDMT: −.497, p = .000;
CVLT: −.334, p = .000; BVMT: −.275, p = .005).
Regarding anxiety and depression symptoms, it was
found that MS group presented higher scores on these
measures than HC, and that these differences were statis-
tically significant: anxiety (MS group: M = 7.85 ± 4.51; HC:
M = 6.32 ± 3.00, t = − 2.348; p = .20) and depression (MS
group: M = 5.14 ± 3.95; HC: M = 3.18 ± 2.57). Anxiety
symptoms were found to be more frequent (n = 56; 53.3%)
than depression symptoms (n = 29; 27.6%) in MS patients.
In the MS group depression symptoms had a modest sig-
nificantly negative effect only on CVLT-II results (R –
0.196; p = .45), whereas anxiety was not significantly corre-
lated with any BICAMS test. The assessment with the
MFIS scale (n = 95) showed that fatigue was present in 50
MS patients (47,4%) and was significantly correlated with
the EDSS score (R – .279; p = .006), and with anxiety (R –
.631; p = .0001) and depression symptoms (R – .754; p
= .0001). Conversely, fatigue was negatively correlated
with SDMT score (R – .266; p = .009); similar results were
observed in both MFIS subscales, physical (M= 18.04 ±
9.66; R-.289; p = .005) and cognitive (M = 17.84 ± 10.21;
R-.203; p = .049).
Discussion
An international consensus committee of experts re-
cently recommended a short battery of tests for cogni-
tive assessment in MS that allows monitoring of
cognition over time and is a fast and reliable instrument
that may be administered by healthcare professionals
with no specific experience in neuropsychological test-
ing. According to the international standards for valid-
ation [15], several validation studies of BICAMS have
been carried out in different cultures and languages,
with the aim of making this psychometric tool more
solid and internationally applicable. Up to now, there ex-
ists normative data for populations of several countries,
such as Czech Republic [32], Italy [34], Hungary [35],
Ireland [36], Brazil [37], Lithuania [38] Argentina [39],
Canada [33], Greece [31], Belgium [40], Japan [41] and
Turkish [42].
The current study followed the recommendations and
standards of the BICAMS consensus committee [14, 15]
and is the first to publish the Portuguese normative data
for SDMT, CVLT-II and BVMT-R. Our results showed
that MS group performed significantly worse than HC
group on all measures (SDMT, CVLT-II and BVMT-R),
a finding that is in agreement with the other recently
published validations. These differences were more
marked in the SDMT and CVLT-II than the BVMT-R,
Table 3 Raw score to scaled score conversions for the BICAMSs
tests
Scaled score SDMT CVLT-II BVMT-R
1 – 0–21 –
2 0–20 22–27 1–3
3 21–24 28–33 4–5
4 25–27 34–37 6–8
5 28–33 38–41 9–10
6 34–37 42–44 11–14
7 38–40 45 15
8 41–45 46–49 16–17
9 46–49 50–53 18–20
10 50–53 54–57 21–22
11 54–57 58–60 23–25
12 58–61 61–64 26–27
13 62–65 65–68 28–30
14 66–69 69–72 31–32
15 70–73 73–76 33–34
16 74–76 77–79 –
17 77–78 – –
Table 4 The prevalence of cognitive impairment in MS patients
according to the 5th percentile value of HC on BICAMS tests
5th Percentile value for HC
on each test
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and similar results were found by O’Connell and col-
leagues (2015), Spedo and colleagues (2015) and Vanotti
and colleagues (2016). Test-retest reliability in our popu-
lation fits the recommended international standards for
BICAMS validation [14]. Test–retest reliability for raw
scores was adequate to excellent for all the three tests in
this validation; more than .80 in SDMT and BVMT, rep-
licating prior finds [33, 34]. Yet our results are lower
than those of Vanotti and colleagues (2016). In addition
we confirmed that the SDMT has particularly high
test-retest reliability. We used a wider time span than
other authors [37, 40] in order to avoid the learning ef-
fect, since at both evaluation times the same forms were
applied.
The BICAMS tasks were able to identify cognitive im-
pairment in 24.8% of MS patients using the criteria of
impairment defined by one or more abnormal tests. This
is a lower value than those found in other studies, which
ranged from 47.3 to 58% [31–33, 35, 36]. This result
may reflect the characteristics of our MS sample, which
were mainly RRMS and rather early cases (mean disease
duration 6.5 years) and a correspondingly low level of
physical disability, median EDSS 1.5 [31–33, 36]. The
lower level of disability in our sample is further sup-
ported by our MSSS data [23].
We found a significant correlation between EDSS and
cognitive performance in the three tests used, that is, the
higher the EDSS score the worse the cognitive test
performance.
Regarding anxiety and depression symptoms, we found
that the MS group also presented with higher scores on
these measures then the HC, fitting the results of other
BICAMS validation studies [32, 33, 37]. The Hungarian
BICAMS validation reported a negative correlation of fa-
tigue with all BICAMS tests [31]. In our study an associ-
ation with fatigue was only seen in the SDMT test,
possibly reflecting the lower fatigue in our patients as
well as the lower physical disability.
This study was some limitations. First, follow-up as-
sessments were done in a low number of cases, espe-
cially in the HC group, which is due to the fact that
some individuals live far from the Hospital and incur
additional personal costs. Another limitation is the fact
that effect size for CVLT and BVMT-R although satisfac-
tory, is on the threshold of the effect size classified as
medium.
Conclusions
In conclusion, our study provides the Portuguese
BICAMS standards for use with MS patients and
evidences the strong psychometric properties of the
Portuguese BICAMS version. The normative data of the
BICAMS for the Portuguese population enables the use
of the battery in clinical practice, for longitudinal patient
assessments and as an outcome measure of cognitive
functioning in clinical trials. Future prospective stud-
ies with larger samples of MS patients, with different
types of disease evolution, will certainly add valuable
information concerning the clinical applicability of the
Portuguese BICAMS version.
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